Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics Inc.

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Applied Therapeutics, with a price target of $0.25. The...

RBC Capital Sticks to Its Hold Rating for Applied Therapeutics (APLT)

In a report released on November 13, Brian Abrahams from RBC Capital maintained a Hold rating on Applied Therapeutics, with a price target of $1.00...

RBC Capital Remains a Hold on Applied Therapeutics (APLT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Applied Therapeutics (APLT – Research Report) and Xilio Therapeut...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APLT	$0.12	-45.92%	37.89M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APLT	$0.12	-45.9%	37.89M
3
4
5
6

APLT

APLT

Get Applied Therapeutics Inc. Data in Excel

Get Applied Therapeutics Inc. Data in Excel